Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

A New EU-Funded Industry-Academia Drug Discovery Partnership Targets Challenging Kinases

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Industry and academia join to create the Translational Kinase Tumor Inhibitor Discovery Consortium.

SARomics Biostructures, Prestwick Chemical and ProQinase together with the University of Turin, Italy, the Israel Structural Proteomics Center (ISPC) at the Weizmann Institute of Science, Israel, and the TechMedIll platform of the University of Strasbourg, France, announce that they have created the Translational Kinase Tumor Inhibitor Discovery Consortium (TAKTIC), funded with €1.1 million by the EU 7th Framework Program “Research for the Benefit of SMEs”.

Targeting kinases has become one of the most important therapeutic opportunities for treating cancer, diabetes, inflammatory diseases and more. The TAKTIC Consortium brings together the unique and proprietary technologies of three SMEs and their knowhow in the field of drug discovery. To this are coupled the extensive expertise in medicinal chemistry, kinase biochemistry and biology of the University of Turin as well as the state-of-the-art high throughput platform for protein expression and crystallization of the Israel Structural Proteomics Centre. The merging of the highly complementary capabilities of the six partners within the TAKTIC Consortium enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases.

“We are excited to coordinate a frontline project of these dimensions, which brings together companies and academic researchers with impressive track records within their respective fields.” says Prof. Salam Al-Karadaghi, project coordinator and Director of Business Development at SARomics Biostructures.

“This exciting project fits with our corporate strategy to generate future value through collaborations with top-tiered SMEs and academic groups” added Prof. Thierry Langer, CEO at Prestwick.

“ProQinase is very pleased to join this attractive project since it brings together complementary expertise from biotech industry and academia creating highly promising synergies in the development of novel anti-cancer drugs” explained Christoph Schächtele, Managing Director of ProQinase.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SARomics Biostructures and Xbrane Bioscience Form a Strategic Partnership
Strategic partnership to deliver “off-the-shelf” protein structure services.
Thursday, January 30, 2014
SARomics Biostructures and Red Glead Discovery Enters into Drug Discovery Collaboration
The companies will perform a joint collaborative project with the goal of developing novel lead compounds against epigenetic pathway targets.
Thursday, October 25, 2012
SARomics Biostructures Brings in New Strategic Owners
Innovationsbron AB and LUIS AB are investing in and becoming new co-owners of the company.
Saturday, September 15, 2012
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos